SCHEMBL3553390

SCHEMBL3553390

CCOC(=O)C1(c2cccc(OCc3ccccc3)c2)N=C(O)C=CN1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
HSP90AA1 P07900 1/20 0.42
KMT2A Q03164 1/20 0.42
ADAM17 P78536 4/20 0.42
MAOB P27338 2/20 0.41
JAK2 O60674 1/20 0.41
JAK3 P52333 1/20 0.41
NR4A2 P43354 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
POLB P06746 1/20 0.40
HTR1A P08908 1/20 0.39
DRD1 P21728 1/20 0.39
HTR2A P28223 1/20 0.39
HTR7 P34969 1/20 0.39
HTR6 P50406 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3558253 0.82 ALOX5 (0.45) ADAM17POLBLMNAKDM4EALDH1A1
SCHEMBL6440684 0.74 ALOX5 (0.56) ADAM17MAOBNR4A2KDM4E
SCHEMBL7807431 0.73 ALOX5 (0.55) ADAM17MAOBKDM4E
SCHEMBL4944704 0.72 ADAM17 (0.49) MEN1HSP90AA1KMT2AADAM17MAOB
SCHEMBL24901890 0.72 ADAM17 (0.49) MEN1HSP90AA1KMT2AADAM17MAOB
SCHEMBL7810873 0.70 ALOX5 (0.67) ADAM17LMNAKDM4EALDH1A1
SCHEMBL11842414 0.67 POLB (0.48) MEN1HSP90AA1KMT2AADAM17MAOB
SCHEMBL340106 0.66 MAOB (0.69) MEN1HSP90AA1KMT2AMAOBNR4A2
SCHEMBL1008116 0.66 LTB4R (0.61) MAOBNR4A2LMNAL3MBTL1KDM4E
SCHEMBL13720748 0.66 PPARA (0.62) MEN1KMT2AMAOBNR4A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7696204-B2 Pharmaceutical compounds LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2010-04-13 US disclosed
US-20090156601-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2009-06-18 US disclosed
US-20090042884-A1 Pharmaceutical Compounds F.HOFFMANN-LA ROCHE AG (CH) 2009-02-12 US disclosed
EP-1951683-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2008-08-06 EP disclosed
WO-2007042810-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042884-A1 Pharmaceutical Compounds PIK3CA, JAK1, PIK3R1 MEN1 2883/4885HSP90AA1 3963/4885KMT2A 3223/4885
US-20090156601-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER NR3C1, NR4A3, NR4A1 MEN1 2033/4885HSP90AA1 4131/4885KMT2A 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.